Owing to the diagnostic dilemma, the prognosis of hepatocellular carcinoma (HCC) remains impoverished, contributing to the globally high mortality rate. Currently, HCC diagnosis depends on the combination of imaging modalities and the measurement of serum alpha-fetoprotein (AFP) levels. Nevertheless, these conventional modalities exhibit poor performance in detecting HCC at early stages. Thus, there is a pressing need to identify novel circulating biomarkers to promote diagnostic accuracy and surveillance. Circulating miRNAs are emerging as promising diagnostic tools in screening various cancers, including HCC. However, because of heterogenous and, at times, contradictory reports, the universality of miRNAs in clinical settings remains elusive. Consequently, we proposed to explore the diagnostic potential of ten miRNAs selected on a candidate-based approach in HCC diagnosis. The expression of ten candidate miRNAs (Let-7a, miR-15a, miR-26a, miR-124, miR-126, miR-155, miR-219, miR-221, miR-222, and miR-340) was investigated in serum and tissue of 66 subjects, including 33 HCC patients and 33 healthy controls (HC), by rt-PCR. Receiver operating characteristic curve (ROC) analysis was used to determine the diagnostic accuracy of the prospective serum miRNA panel. To anticipate the potential biological roles of a three-miRNA signature, the target genes were evaluated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway. The serum and tissue expression of miRNAs (Let-7a, miR-26a, miR-124, miR-155, miR-221, miR-222, and miR-340) were differentially expressed in HCC patients (p < 0.05). The ROC analysis revealed promising diagnostic performance of Let-7a (AUC = 0.801), miR-221 (AUC = 0.786), and miR-2 (AUC = 0.758) in discriminating HCC from HC. Furthermore, in a logistic regression equation, we identified a three-miRNA panel (Let-7a, miR-221, and miR-222; AUC = 0.932) with improved diagnostic efficiency in differentiating HCC from HC. Remarkably, the combination of AFP and a three-miRNA panel offered a higher accuracy of HCC diagnosis (AUC = 0.961) than AFP alone. The functional enrichment
Introduction

Globally, hepatocellular carcinoma (HCC) is the third primary cause of cancer-allied mortality and accounts for 90% of primary liver cancers (Yang et al., 2019) (Fattovich et al., 2004; Jemal et al., 2011). Often, HCC is diagnosed at an advanced stage, and due to rapid tumor progression, most HCC patients die early. More than 80% of patients with underlying cirrhosis develop HCC, and, amongst these, only 10% are potentially resectable at the time of detection (Yang and Roberts, 2010; Llovet et al., 2021). The remainders are unresectable because of location, size, or severity of underlying liver disease (Zhang et al., 2014a). Consequently, to improve prognosis, an earlier HCC diagnosis is vital (Bargellini et al., 2014). These imaging techniques are routinely combined with the use of serum tumor markers, such as a-fetoprotein (AFP), which is the most commonly used biomarker to detect HCC. Although several western countries have discontinued using AFP due to its poor sensitivity and precision, this protein is still widely used in many Asian countries, including India (Patel et al., 2012). Although the precise molecular mechanisms involved in the development and progression of HCC remain elusive, various risk factors for HCC development are well defined. HBV infection and aflatoxin B exposure are the major risk factors for HCC in high-incidence countries such as Asia and Africa, whereas HCV virus infection, alcohol consumption, and metabolic syndromes are crucial risk factors in low-incidence countries such as Europe, North and South America, and the Middle East. In addition, increased body mass index (BMI) and diabetes, which can lead to non-alcoholic steatohepatitis (NASH), are both substantial risk factors for HCC (Noureddin and Rinella, 2015). This is particularly alarming in view of the rising obesity epidemic in children and adults over the last 25 years (Bhasin Lal et al., 2015). Despite this, around 70–80% of HCC cases emerge from a background of liver cirrhosis, with a median period of 10 years to HCC development (Parkin et al., 2005; Patel et al., 2012). Overall, the poor prognosis and high mortality of HCC are attributable to the underlying cirrhosis, adverse early diagnosis, and paucity of effective late-stage therapy choices (Aleman et al., 2013). This establishes an urgent need to find sensitive markers, especially those correlated with early diagnosis and also for monitoring postoperative recurrence in order to stipulate adequate treatment for HCC. MicroRNAs (miRNAs) are a vital component of the short non-coding RNA family that governs endogenous RNA interference in almost 30% of protein-coding genes by pairing with the 3' untranslated region (UTR) of mRNA targets, resulting in post-transcriptional and/or post-translational repression (Friedman et al., 2009). miRNAs are known to regulate a broad range of key biological functions, including differentiation, development, proliferation, apoptosis, migration, and invasion in normal cells (Giovannetti et al., 2012). Lately, formidable evidence suggests that miRNAs enact as oncogenes or tumor suppressors, thereby facilitating neoplastic transformation in innumerable cancers (Vaz et al., 2015). Numerous studies have recently reported the potential clinical utility of circulating miRNAs in the diagnosis and prognosis of HCC (Arrese et al., 2015). As a result, further research on dysregulated miRNA expression could lead to the identification of novel miRNA biomarkers for HCC. Based on a comprehensive literature review, a panel of ten candidate miRNAs (Let-7a, miR-340, miR-221, miR-222, miR-219, miR-155, miR-126, miR-124, miR-26a, and miR-15a) reported in diverse cancers including HCC were selected for further extensive investigation (Ladeiro et al., 2008; Lawrie et al., 2008; Melo and Esteller, 2011; Cheng et al., 2011; Borel et al., 2012; Anwar and Lehmann, 2015; Arrese et al., 2015; Li et al., 2015; Vasuri and Wang, 2015; Zhuang and Meng, 2015; Dong et al., 2016; He et al., 2018; Wu et al., 2018; Chirichev et al., 2019; Ravegnini et al., 2019; Zhou et al., 2019; Zhu et al., 2020; Liu et al., 2021; Zhang et al., 2021). Prominently, tissue specificity is an essential property of specific biomarkers to perceive cancer progression. Thus, we performed validation in HCC tissues compared to adjacent peritumor sections to confirm the liver-originating serum miRNAs in HCC diagnosis.
Materials and methods

Patients and specimen collection

Following stringent inclusion and exclusion criteria, a total of 66 subjects (33 HCC patients and 33 healthy controls) were recruited between January 2018 to December 2020 from the department of Surgical Gastroenterology, Medical Gastroenterology and Radio-diagnosis, Sher-I-Kashmir Institute of Medical Sciences (SKIMS). The details of all participants were collected through a comprehensive questionnaire along with signed informed consent in accordance with approved guidelines of the SKIMS institutional ethics committee (IEC/SKIMS Protocol # RP: 96/2018). The HCC cases enlisted in the study were histopathologically confirmed by liver biopsy or by the radiological findings encompassing abdominal ultrasound (USG), computed tomography (CT) abdomen, magnetic resonance imaging (MRI), or by virtue of elevated serum AFP levels (AFP ≥ 200 μg/ml). Healthy volunteers with no known significant health issues were included as a control group in this research. Additionally, information on clinical features such as BCLC & TNM staging was collected from medical records.

3 ml peripheral blood samples were collected by venous puncture in non-EDTA vacutainers and centrifuged at 4500 x rpm for 10 min at room temperature (RT) to separate the serum fraction for miRNA extraction. Without disturbing the pellet, sera were transferred to fresh collection tubes and stored at −80°C for further analysis. The hemolyzed samples were excluded from the study. Fresh frozen HCC and paired peritumor specimens were collected from HCC patients undergoing surgical resection.

RNA isolation

The isolation of miRNA from tissue and plasma was done using miRNAeasy Mini Kit (# 1038703, QIAGEN, Germany) and miRNAeasy® Serum/Plasma Kit (# 1071073, QIAGEN, Germany), respectively, by following the manufacturer’s protocol. The concentration and purification of extracted miRNA from tissue and serum/plasma were measured by micro-volume UV-Vis spectrophotometer (Thermo Scientific NanoDrop 2000) at 260 nm wavelength using A260/A280 ratio. cDNA was synthesized using a universal cDNA kit (# QIAGEN, 21816, Germany). The concentration for each RNA template was adjusted to 5 ng/μL by using nuclease-free water.

Real-time PCR amplification for the expression of miRNA in tissue and plasma

MiRCURY LNA™ SYBR Green PCR kit (#339346, QIAGEN, United States), commercially designed primers, cDNA, and nuclease-free water were used for amplification of the product. The desired master mix was prepared from the abovementioned reagents in a tube, and the obtained mixture was mixed well by vortexing and spun down. The mixture was dispensed in tubes, and cDNA was diluted (1:60) in nuclease-free water and added to these tubes separately. The tubes were placed in a thermocycler (Rotor-Gene Q MDx, QIAGEN, working on Q-Rex software, Germany) by following reaction conditions as 95°C for 2-min, followed by 40 cycles of denaturation at 95°C for 10-min, annealing at 56°C for 1-min, and melting curve at 60–95°C. U6 was used as an internal reference gene. The ΔΔCt model was used for the relative quantification of RT-PCR data of miRNA.

Target genes for miRNA signature prediction

From three different miRNA target gene prediction websites, namely, miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/), TargetScan (http://www.targetscan.org), and miRDB (http://www.mirdb.org/), the database for miRNA prediction was downloaded. The Perl language was used to find miRNA signature targeted genes, which are covered by at least 2 databases. The relationship between miRNAs and target genes was plotted using a Venn diagram and map network.

Functional enrichment analysis of target genes

The enrichment analysis for predicted genes of potential miRNAs was performed by Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) by using the DAVID database (http://david.abcc.ncifcrf.gov/).

Statistical analysis

A statistically relevant sample size was calculated by open EPI Statistical Software. All the data are presented as the mean ± SD and/or mean ± SE. The statistical analysis, i.e., “t-test”, Spearman correlation (r), univariate logistic regression analysis, stepwise logistic regression analysis and receiver operator curve (AUC), and Kruskal–Wallis test were performed using SPSS version 17.0 (IBM, Chicago, IL, United States), and all figures were generated using GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA, United States). p < 0.05 were considered statistically significant.
The age and gender distribution were indistinguishable in both participating study groups, whereas the liver function parameters of serum bilirubin, ALT, AST, ALP, and AFP were significantly deranged among the participants of the HCC group compared to those of the HC group. Furthermore, HCC patients had a considerable reduction in platelet counts compared to that in HC patients. However, there were no variations in the serum protein and albumin levels and rates of PT and INR concentration across the two groups. According to CT imaging, 20 of the 33 HCC participants in the study had tumors larger than 5 cm (60%), while 13 had tumors smaller than 5 cm (39%). BCLC 0/A, B/C, and D scores were recorded in 8 (24%), 18 (54%), and 2 (6%) patients, respectively, indicating all patients were in the intermediate to late stages of the disease. In terms of TNM staging, four cases were registered in TNM-I, nine cases in TNM-II, eight cases in TNM-III, and 12 cases in TNM-IV. The demographic features of the study groups, as summarized in Table 1, certify that the subjects recruited in the study are properly classified and accurately represent the allocated group.
Screening and validation of candidate miRNAs differentially expressed in HCC

Serum expression profiles for the panel of ten miRNAs, entailing (Let-7a, miR-15a, miR-26a, miR-124, miR-126, miR-155, miR-219, miR-221, miR-222, and miR-340) between 33 HCC and 33 HC subjects were observed by real-time qPCR. Our results indicate downregulation of serum miR-221 (p < 0.001), miR-340 (p < 0.003), miR-126 (p < 0.001), miR-219 (p < 0.01), and miR-155 (p < 0.04) between HCC and control group. Furthermore, Let-7a (p < 0.0001), miR-26a (p < 0.04), miR-124 (p < 0.007), and miR-222 (p < 0.005) were downregulated in serum of HCC patients compared to that in HC patients. Furthermore, the expression of miR-15a was non-significant when compared among the groups (Figure 1).

To further verify the tissue expression profile of the listed miRNAs, the expression levels were measured in 33 tumor and paired peritumor tissues of HCC patients by qPCR. Among the 33 matched samples, miR-221 (p < 0.0001), miR-124 (p < 0.003), miR-340 (p < 0.03), miR-222 (p < 0.005), and miR-155 (p < 0.0001) exhibited significantly higher expression, while Let-7a (p < 0.0007) and miR-26a (p < 0.0006) showed marked lower expression in the tumor tissues of HCC patients compared to the peritumor counterparts. Nevertheless, no significant differential expression was found in miR-126, miR-15a, and miR-219 among the groups (Figure 2).

Clinical significance and diagnostic accuracy of candidate miRNAs in HCC diagnosis

To validate the discriminatory potential of significantly deranged miRNAs, the area under the curve (AUC) was determined using ROC analysis. Among nine differentially expressed serum miRNAs in HCC patients, Let-7a showed the best diagnostic efficacy with the highest AUC value (AUC = 0.801, 95% CI of 0.684–0.919, and at a cut off <0.9121, sensitivity
of 83.33%, and a specificity of 68.97%; \( p < 0.001 \), followed by miR-221 (AUC 0.786, 95% CI = 0.666–0.906, cut off <1.626; 228, sensitivity 77.14%, specificity 80.77%, \( p < 0.0001 \)), and miR-222 (AUC 0.758, 95% CI = 0.583–0.932, cut off >0.609; sensitivity 86.96%, specificity 68.75%, \( p < 230 0.0067 \)). Furthermore, miR-26a (with AUC 0.531), miR-124 (AUC 0.668), miR-340 (AUC 0.548), miR-126 (AUC 0.527), and miR-155 (AUC 0.583) were unable to distinguish HCC patients from HC, as shown in Figure 3.

Establishment of the predictive three-miRNA panel and to evaluate its efficacy for diagnosis

Based on the univariate logistic regression model, the levels of Let-7a (\( p < 0.001 \)), miR-221 (\( p < 0.0001 \)), and miR-222 (\( p < 0.004 \)) depicted considerable variation among HCC patients and healthy controls and, thus, were accordingly included in the further verification, as shown in Table 2.

Altogether, the three chosen miRNAs were found to be significant predictors for HCC, as shown in Table 3. To assess the predicted likelihood of being diagnosed with HCC, the logit model \[ \text{logit} (p) = 0.997 + 3.641 \times (\text{Let-7a}) -2.985 \times (\text{miR-221}) + 5.438 \times (\text{miR-222}) \] was used to construct the ROC curve. Our analysis affirmed that the AUC of the three-miRNA panel was 0.932 (\( p < 0.0001 \)), with a sensitivity and specificity of 93.75% and 84.62%, respectively, as shown in Figure 4.

Compounding accuracy of three-miRNA signature and AFP for the diagnosis of HCC

A step-wise logistic regression model was utilized to analyze the performance of the three-miRNA panel in combination with
AFP in discriminating HCC from HC. ROC analysis revealed that the combination of miRNAs (Let-7a, miR-221, and miR-222) had a significant superiority (AUC = 0.961; 95% CI = 0.882), than each miRNA separately; viz let-7a (AUC = 0.801, 95% CI = 0.684–0.919), miR-221 (AUC = 0.786, 95% CI = 0.666–0.906), and miR-222 (AUC = 0.758, 95% CI = 0.583–0.932) and AFP alone (AUC = 0.766; 95% CI = 0.632–0.901) in discriminating patients with HCC from those with HC. Additionally, our data suggest that the diagnostic efficacy of Let-7a and miR-221 alone could be further improved by incorporating miR-222.

TABLE 2 Establishment of the predictive three-miRNA panel and to evaluate its efficacy for diagnosis: univariate logistic regression analysis of candidate miRNAs. The statistical analysis was done using GraphPad Prism 5.0.

| miRNAs      | Estimate | Std. Error | p-value |
|-------------|----------|------------|---------|
| hsa-Let-7a-5p | 2.426    | 0.997      | <0.001  |
| hsa-miR-221-3p | -3.175   | 1.105      | <0.0001 |
| hsa-miR-222-5p | 5.098    | 1.968      | <0.004  |

TABLE 3 Stepwise logistic regression analysis of candidate miRNAs. The statistical analysis was done using GraphPad Prism 5.0.

| miRNAs      | Estimate | Std. Error | p-value | Optimal cut-off | Diagnostic performance |
|-------------|----------|------------|---------|----------------|-----------------------|
| Intercept   | 0.997    | 0.245      | <0.0001 | <7.895         | AUC = 0.932            |
| Let-7a      | 3.641    | 1.420      | 0.004   |                | CI = 0.845–1.02       |
| miR-221     | -2.985   | 1.088      | 0.0005  |                | Sensitivity = 93.75%   |
| miR-222     | 5.438    | 2.721      | 0.0132  |                | Specificity = 84.62%   |
was superior to that of AFP, while miR-222 had a diagnostic efficiency equal to that of AFP, as shown in Table 4.

Expression of three-miRNA panel signature in viral etiology (HBV/HCV)-related HCC

In a further detailed analysis, we investigated serum Let-7a, miR-221, and miR-222 expression profiles in patients with hepatitis B- and hepatitis C-associated HCC. Using the non-parametric Kruskal–Wallis test, we examined that the expressions of three studied miRNAs were significantly different in the sera and tissue of hepatitis B infected, hepatitis C infected, and non-viral groups compared to the healthy controls and peritumor samples \( (p < 0.05) \), respectively. No significant difference was found in miRNA levels among hepatitis B infected, hepatitis C infected, and non-viral groups (Figures 5 and 6).

The correlation of serum Let-7a, miR-221, and miR-222 expression and clinical indicators of patients with HCC

Next, to investigate whether an altered expression profile of serum Let-7a, miR-221, and miR-222 is indicative of HCC diagnosis, the clinical correlation was measured. No
FIGURE 5
Differential serum expression levels of (A) Let-7a, (B) miR-221, and (C) miR-222 in non-B/C (non-hepatitis B and non-hepatitis C), CHB (chronic hepatitis B), and CHC (chronic hepatitis C) groups of patients compared to peritumor tissue were measured by rt-qPCR. The statistical analysis was done using Mann–Whitney test (GraphPad Prism 5.0). The statistically significant p-value was denoted as < 0.05. NS; non-significant.

FIGURE 6
Differential tissue expression of (A) Let-7a, (B) miR-221, and (C) miR-222 in non-B/C (non-hepatitis B and non-hepatitis C), CHB (chronic hepatitis B), and CHC (chronic hepatitis C) groups compared to peritumor tissue were measured by rt-qPCR. The statistical analysis was done using Mann–Whitney test (GraphPad Prism 5.0). The statistically significant p-value was denoted as < 0.05. NS; non-significant.
A significant association was found between age, gender, S.Bil, S.ALT, S.AST, S.protein, S.albumin, PT, INR, S.AFP, and BCLC/TNM staging and the expression of Let-7a, miR-221, and miR-222.

**Prediction of target genes for the three miRNAs**

The target genes regulated by the three miRNAs were predicted by three databases. To further enhance the reliability of the bioinformatic analysis, the overlapping target genes were identified using Venn diagrams and network maps.
genes were identified. The results indicated that 395, 101, and 443 overlapping genes were identified for Let-7a, miR-221, and miR-222, respectively, by the three databases mentioned previously, which were shown using a Venn diagram (Figure 7).

A total of 1207, 990, and 5874 for hsa-Let-7a-5p, 504, 615, and 6233 for hsa-miR-221-3p, and 3858, 601, and 4380 for hsa-miR-222-5p target genes were predicted using three databases viz. TargetScan, miRDB, and mirMap, respectively. To clarify whether the target genes of these miRNAs are likely to participate in the progression of HCC, the intersection of target mRNAs for downregulated miRNAs (hsa-Let-7a-5p) and upregulated mRNAs and target mRNAs for upregulated miRNAs (hsa-miR-221-3p and hsa-miR-222-5p) and downregulated mRNAs were taken. The results were performed on a total of 1,034 genes, including 780 upregulated genes and 254 downregulated genes, respectively. The network between the three miRNAs and their 1034 target genes is shown in Figure 8.

Functional enrichment analysis of target genes associated with HCC

In order to perceive the structured features and biological interpretation of the 1034 predicted target genes, the Gene Ontology (GO) annotation was conducted using the AVID database. The results for the three listed categories of GO, comprising cellular component (CC), biological process (BP), and molecular function (MF), were demonstrated in a pie chart. Among the top ten particulars of target genes, BP analysis mostly includes metabolic process, biological regulation, and organic substance metabolic process. Furthermore, CC analysis mainly contained cell, cell part, and organelle, while MF analysis mainly contained binding, protein binding, and organic cyclic compound binding (Figure 9). The results of KEGG pathways enrichment analysis about the target genes associated with HCC were mainly enriched in the microRNAs in cancer, oncogene induction senescence, pancreatic adenocarcinoma pathway, Fas ligand pathway, stress induction of heat shock proteins regulation, and hepatitis C and HCC pathway (Figure 10 and Supplementary Figures S1 and S2).

Discussion

HCC is the fifth most prevalent malignancy and the second dominant cause of cancer-related mortality worldwide, with a 5-year survival rate of barely 5%, making it the third most lethal malignancy (Huang et al., 2021). The dismal prognosis of HCC is mostly owing to the late diagnosis of this disease. Hence, early detection of HCC can facilitate effective treatment and minimize disease mortality. Currently, serum levels of liver enzymes such as ALT, AST, glutamyl transpeptidase (GGT), and AFP are being utilized as biomarkers to assess liver damage and therapy response (Gowda et al., 2009). Even so, ALT, AST, and
alkaline phosphatase levels might also be raised as a result of muscle and bone injury (Giannini et al., 2005). In addition to this, numerous novel serum indicators, such as DCP and AFP-L3, have been found to have higher diagnostic efficacy for HCC, yet these have to be widely verified in routine clinical practice (Zhou et al., 2021). This raises concerns about the specificity of existing diagnostic markers utilized in clinics, necessitating a deeper knowledge of the present liver-specific biomarkers. Furthermore, since HCC is frequently identified at an advanced stage, resulting in severe liver damage and restricted treatment choices, new sensitive biomarkers should be sought to overcome early detection.

Recently, miRNAs have emerged as novel non-invasive biomarkers for the diagnosis and prognosis of various human cancers, including HCC. Importantly, a number of studies have documented the tissue- or organ-specific expression of microRNAs, suggesting the high specificity of microRNAs as biomarkers. Since the first report on the use of microRNA as potential diagnostic biomarkers by Lawrie et al. in 2008 on large B-cell lymphoma, the notion has been pursued in a number of studies involving various other cancer types, including the potential use of circulating miRNAs as biomarkers for HCC (Yang et al., 2019). An extensive and considerable number of studies have reported dysregulation of microRNAs during the initiation and progression of HCC. These studies were largely based on comparisons between malignant, benign, and pre-cancerous lesions compared with a healthy liver or adjacent peritumoral tissues. The approach of direct measurement of tissue microRNAs is challenging as invasive biopsy or surgery is required for collecting tissue samples. Conversely, circulating microRNAs provide an alternative non-invasive approach to be used as tumor biomarkers. Notably, the level of liver microRNAs has been found to correlate with serum microRNA levels in many studies (Shao et al., 2019; Mohamed et al., 2020). One of the major advantages of mature microRNAs as biomarkers is their stability in body fluids such as serum, plasma, urine, saliva, and cerebrospinal fluid over a wide range of temperatures (Ting et al., 2020). Mature microRNAs are complexed with AGO2 or other argonaute proteins, thereby augmenting their stability (Yang et al., 2018). Liver microRNAs may be secreted into the circulation passively through apoptosis and necrosis as ribonucleoprotein complexes or may be transported within viral particles such as HBV surface antigen (HBsAg) or enclosed within exosomes/microvesicles (Shimizu et al., 2010; Yang et al., 2018; Singal et al., 2020). Therefore, the capability to measure microRNA levels secreted in the serum might stipulate a way to estimate microRNA activity in the liver.

In recent years, several miRNAs have been proposed to exhibit high diagnostic accuracy in discriminating patients with HCC from healthy controls. Studies have shown serum miR-143 and miR-215 as promising biomarkers for hepatocellular carcinoma (Zhang et al., 2014b). Xie et al. found that miR-101 could significantly differentiate HBV-HCC from HBV-associated liver cirrhosis (Moeni et al., 2012). Another study reported serum miR-150 as a biomarker for the diagnosis and prognosis of HCC patients (Joyce and Pollard, 2009). Li et al. classified miR-18a as a potential biomarker for screening hepatitis B virus-related HCC
(Hatziapostolou et al., 2011). (El-Ahwaney et al., 2019) So far, the conclusions on the use of serum miRNAs as non-invasive biomarkers have been contradictory, and efforts to develop a less-invasive approach using serum miRNA combination have met limited success. Thus, in the present study, we hypothesized that inclusion of additional markers, such as miRNAs, might further increase the value of the HCC diagnosis investigations.

Consequently, based on the comprehensive literature review, a panel of ten miRNAs (Let-7a, miR-221, miR-26a, miR-124, miR-222, miR-340, miR-126, miR-15a, miR-219, and miR-155) that were reported in diverse cancers together with HCC was chosen for the study.

In order to examine the regulation of differentially expressed miRNAs in hepatocellular carcinoma, regulation of the panel of ten miRNAs (Let-7a, miR-221, miR-26a, miR-124, miR-340, miR-126, miR-15a, miR-219, and miR-155) selected on the basis of literature and In Silico analysis was carried out in HCC patients. Our results indicated that miR-221, miR-340, miR-126, miR-219, and miR-155 were upregulated, whereas Let-7a, miR-26a, miR-124, and miR-222 were downregulated in HCC patients compared to HC. However, the expression of miR-15a was non-significant when compared among the groups (Figure 1).

Correspondingly, while investigating the tissue levels, we found the high expression of miR-221, miR-124, miR-340, miR-222, and miR-155 and low expression of Let-7a and miR-26a in the tumor tissue of HCC patients compared to their peritumor counterparts. Nevertheless, the expression of miR-126, miR-15a, and hsa-miR-219 was found to be non-significant (Figure 2).

Furthermore, our data indicated that among the nine differentially expressed miRNAs, Let-7a showed the best diagnostic efficacy, followed by miR-221 and miR-222, whereas miR-26a, miR-124, miR-340, miR-126, and miR-155 were unable to distinguish HCC patients from HC patients (Figure 3).

Subsequently, a step-wise logistic regression model was utilized to analyze the performance of the three-miRNA panel in combination with AFP in discriminating HCC from HC. We found that the combination of Let-7a, miR-221, and miR-222 had a significant superiority over each miRNA separately and AFP alone in distinguishing HCC patients from HC. Additionally, our data also suggested that the diagnostic efficacy of Let-7a and miR-221 alone were superior to that of AFP, while miR-222 had a diagnostic efficiency equal to that of AFP (Figure 4).

Subsequently, with the aim to understand the interactome of predicted target genes for Let-7a, miR-221, and miR-222, a total of 1,034 intersecting genes predicted by three bioinformatic tools were used to construct the miRNA-mRNA interaction network (Figure 8). Among the top ten particulars of target genes, BP analysis mostly includes metabolic process, biological regulation, and organic substance metabolic process. Furthermore, CC analysis mainly contained cell, cell part, and organelle, while MF analysis mainly contained binding, protein binding, and organic cyclic compound binding (Figure 9). KEGG pathway enrichment analysis revealed that the genes were mainly enriched in the microRNAs in cancer, oncogene induction senescence, pancreatic adenocarcinoma pathway, and hepatitis C and HCC pathway, indicating possible crosstalk of miRNAs in cancer with HCC (Figure 10 and Supplementary Figures S1 and S2).

**Conclusion**

In conclusion, we identified three miRNAs: Let-7a, significantly expressed at a lower level, and miR-221 and miR-222, significantly expressed at higher levels, in HCC patients compared to HC volunteers. Based on the ROC analysis, we propose that these three miRNAs can be feasible noninvasive HCC biomarkers. Notably, the panel of the three miRNAs (Let-7a, miR-221, and miR-222) showed the best diagnostic performance than a single miRNA. In a profound analysis, we found that plasma Let-7a, miR-221, and miR-222 expression profiles were common to patients with hepatitis B- and hepatitis C-associated HCC irrespective of the underlying etiology. It is, thus, worthwhile to validate the use of the three-miRNA panel reported in our study for second-line testing in a larger cohort of patients and elucidate the underlying mechanism of the deregulation of circulatory miRNAs. Furthermore, the possible function is inferred by predicting the model for target genes, which improves our understanding of HCC carcinogenesis and progression. To our knowledge, this is the first clinical study that delineated the role of a three-miRNA-panel (comprising Let-7a, miR-221, and miR-222) in the non-invasive diagnosis and plausible therapeutic management of HCC patients. Given the critical role of Let-7a, miR-221, and miR-222 in HCC development, this three-miRNA-panel may improve risk prediction and furnish new insights into the pathological mechanism of HCC development. Together with AFP, this three-miRNA-panel reposes better efficacy in discriminating HCC patients from healthy controls (HCs) than the existing miRNA-based biomarkers. This study may also help in the identification of novel targets for the therapeutic intervention of HCC and may provide a rationale for improving existing cancer therapies, prominently driven by the fact that both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections result in chronic hepatitis paramounting to the HCC development. Furthermore, the expression of miRNAs in response to HBV and HCV infection varies dramatically between the two viruses. Henceforth, the early detection and rapid development of new therapeutic antivirals for HCC necessitate the discovery of novel miRNA biomarkers common to the array of all etiologies.
Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by IEC/Sher-I-Kashmir Institute of Medical Sciences Protocol # RP-96/2018. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

TY carried out the experiments and drafted the manuscript. SD planned the experiments and was involved in writing the manuscript. SA, NC, ZR, and AS were involved in patient enrollment and collection of clinical samples. RR critically evaluated the manuscript. TY, SD, and RR performed the statistical analysis. DA was involved in conceiving the project, planning the experiments and overall analysis of the manuscript, and arranging intramural grants for the study. All the authors finally approved the manuscript.

Funding

The study was funded by the intramural grants approved by Sher-I-Kashmir Institute of Medical Sciences.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.929787/full#supplementary-material

References

Acunzo, M., Romano, G., Wernicke, D., and Croce, C. M. (2015). MicroRNA and cancer—a brief overview. Adv. Biol. Regul. 57, 1–9.

Aleman, S., Rabben, N., Weiland, O., Davidsdottir, L., Hedenstierna, M., Rose, N., et al. (2013). A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin. Infect. Dis. 57, 230–236.

Anwar, S. L., and Lehmann, U. (2015). MicroRNAs: Emerging novel clinical biomarkers for hepatocellular carcinomas. J. Clin. Med. 4, 1631–1650. doi:10.3390/jcm40601361

Arrese, M., Eguchi, A., and Feldstein, A. E. (2015). Circulating microRNAs: Emerging biomarkers of liver disease. Semin. Liver Dis. 35, 43–54. doi:10.1055/s-0034-1397348

Bergellini, I., Battaglia, V., Bozzi, E., and Luca, D. (2014). Radiological diagnosis of hepatocellular carcinoma. J. Hepatol. Carcinoma 1, 137–148. doi:10.2147/JHC.844379

Bhasin Lal, S., Venkatesh, V., Kumar, A., and Aneja, A. (2021). Liver abscess in children-experience from a single tertiary care center of North India: Etiology, clinical profile and predictors of complications. J. Pediatr. Infect. Dis. doi:10.1097/INF.0000000000000553

Borel, F., Konstantinova, P., and Jansen, P. L. (2012). Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J. Hepatol. 56, 1371–1383. doi:10.1016/j.jhep.2011.11.026

Cheng, S. Q., Wang, H., Li, N., Chen, Y. F., and Gao, C. F. (2011). Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic Hepatitis B virus infection. PLoS One 6, e28486. doi:10.1371/journal.pone.0028486

Chiribehv, E., Obeng, K. C., Ioffe, Y. J., and Unternehrer, J. J. (2019). Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin. Transl. Med. 8, 24.

Dong, Y., Pa, C., Guan, H., Zhang, Z., Zhou, T., and Li, B. (2016). Prognostic significance of miR-126 in various cancers: A meta-analysis. Oncotargets Ther. 9, 2547–2555.

El-Ahwany, E. G. E., Mourad, L., Zohairy, M. M. K., and Abu-Taleb, H. (2019). MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. Arch. Med. Sci. doi:10.5114/ams.2019.86621

Fattovich, G., Stroffolini, T., Zagni, I., and Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127, 535–550. doi:10.1053/gastro.2004.09.014

Friedman, R. C., Farh, K. K., Burge, C. B., and Bartel, D. P. (2009). Most mammalian miRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105. doi:10.1101/gr.082701.108

Gannu, M. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics. CA Cancer J. Clin. 55, 74–108.

Giovannetti, E., Erozenci, A., Smit, J., Danesi, R., and Peters, G. J. (2012). Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 81, 103–122. doi:10.1016/j.critrevonc.2011.03.010

Gowda, S., Desai, P. B., Hull, V. V., and Math, A. A. K. (2009). A review on laboratory liver function tests. Pan. Afr. Med. J. 22 (3), 17.

Hatziospostolou, M., Polytechnou, C., Aggelidou, E., Drakaki, A., Poultides, G. A., Jaeger, S. A., et al. (2011). An HNF4a-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 147, 1233–1247.

He, R. Q., Yang, X., Liang, L., Chen, G., and Ma, J. (2018). MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study. Oncol. Lett. 15, 5517–5522.

Huang, G. L., Guo, H. Q., Guo, C. C., Li, H., Ye, S., Ling, S., et al. (2010). Circulating miR-221 directly amplified from plasma is a potential diagnostic and
prognostic marker of colorectal cancer and is correlated with p53 expression. *J. Gastroenterol. Hepatol.* 25, 1674–1680.

Huang, Z., Xu, Y., Wan, M., Zeng, X., and Wu, J. (2021). miR-340: A multifunctional role in human malignant diseases. *Int. J. Biol. Sci.* 17, 236–246.

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. *Ca. Cancer J. Clin.* 61, 69–90. doi:10.3322/caac.20107

Joyce, J. A., and Pollard, J. W. (2009). Microenvironmental regulation of metastasis. *Nat. Rev. Cancer* 9, 239–252. doi:10.1038/nrc2618

Kim, V. N. (2005). MicroRNA biogenesis: Coordinated cropping and dicing. *Nat. Rev. Mol. Cell. Biol.* 6, 376–385. doi:10.1038/nrm1644

Ladeiro, Y., Choisy, G., Balabaud, C., Boulac-Sage, P., Pelletier, L., Reboissou, S., et al. (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. *Hepatology* 47, 1955–1963. doi:10.1002/hep.22256

Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkar, B., Liggett, A. P., Pulford, K., et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br. J. Haematol.* 141, 672–675.

Li, H., Li, X. Y., Liu, L. H., Sun, W., and Xiao, T. (2015). Prognostic role of MicroRNA-126 for survival in malignant tumors: A systematic review and meta-analysis. *Dis. Markers* 2015, 739469.

Liu, W., Hu, K., Zhang, F., Lu, S., Chen, R., Ren, Z., et al. (2021). The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis. *Int. J. Biol. Markers* 36, 17246008211032689.

Llovet, J. M., Kelley, R. K., Villanueva, A., and Sing, A. G. (2021). Hepatocellular carcinoma. *Nat. Rev. Disease Primers* 7, 6. doi:10.1038/s41571-020-00240-3

Melo, S. A., and Esteller, M. (2011). Dysregulation of microRNAs in cancer: Playing with fire. *FEBS Lett.* 585, 2087–2099. doi:10.1016/j.febslet.2010.08.009

Moenni, A., Cornella, H., and Villanueva, A. (2012). Emerging signaling pathways in hepatocellular carcinoma. *Liver Cancer* 1, 83–93. doi:10.1159/000342405

Mohamed, A. A., Omar, A. a. A., El-Awady, R. R., Hassan, S. M. A., Eitah, W. M. S., Ahmed, R., et al. (2020). MiR-155 and MiR-665 role as potential non-invasive metastasis. *Nat. Rev. Cancer* 20, 1955.

Noting, N., Sammarrini, G., Zanotti, F., Berrone, J. L., Hreha, P., et al. (2019). Prognostic role of miR-221 and miR-222 expression in cancer patients: A systematic review and meta-analysis. *Cancers (Basel)* 11, 1030.

Shao, C., Yang, F., Qin, Z., Jing, X., Shu, Y., and Shen, H. (2019). The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: A systematic review with meta-analysis. *BMC Cancer* 19, 1103.

Shimizu, S., Takehara, T., Hikita, H., Kodama, T., Miyagi, T., Hosui, A., et al. (2010). The let-7 family of microRNAs inhibits Bcl-xl expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. *J. Hepatol.* 52, 698–704.

Singal, A. G., Lamperico, P., and Nalon, P. (2020). Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J. Hepatol.* 72, 250–261. doi:10.1016/j.jhep.2019.08.025

Ting, G., Li, X., Kwon, H. Y., Ding, T., Zhang, Z., Chen, Z., et al. (2020). microRNA-219-5p targets NEK6 to inhibit hepatocellular carcinoma progression. *Am. J. Transl. Res.* 12, 7528–7541.

Vasuri, B., and Wang, G. (2015). MicroRNAs involved with hepatocellular carcinoma (Review). *Onco. Rep.* 34, 2811–2820. doi:10.3892/or.2015.4275

Vaz, J., Ansari, D., Saso, A., and Andersson, R. (2015). Spara: A potential prognostic and therapeutic target in pancreatic cancer. *Pancreas* 44, 1024–1035. doi:10.1097/MPA.0000000000000409

Wu, L. P., Wu, J., Shang, A., Yang, M., Li, L. L., Yu, J., et al. (2018). miR-124 inhibits progression of hepatocarcinoma by targeting KLF4 and promises a novel diagnostic marker. *Artif. Cells Nanomed Biotechnol.* 46, 159–167.

Yang, J. D., and Roberts, L. R. (2010). Hepatocellular carcinoma: A global view. *Nat. Rev. Gastroenterol. Hepatol.* 7, 448–458. doi:10.1038/nrgastro.2010.100

Yang, F. R., Li, H. J., Li, T. T., Zhao, Y. F., Liu, Z. K., and Li, X. R. (2019). Prognostic value of MicroRNA-15a in human cancers: A meta-analysis and bioinformatics. *Biomed. Res. Int.* 2019, 2063823.

Yang, J., Sheng, Y. J., Wei, J. W., Gao, X. M., Zhu, Y., Jia, H. L., et al. (2018). MicroRNA-219-5p promotes tumor growth and metastasis of hepatocellular carcinoma by regulating cadherin 1. *Biomed. Res. Int.* 2018, 4793971.

Zhang, J. Y., Chen, J., Xu, Y., Song, N. H., and Yin, C. J. (2014a). Prognostic role of microRNA-221 in various human malignant neoplasms: A meta-analysis of 20 related studies. *PloS One* 9, e87606.

Zhang, W. T., Zhang, G. X., and Gao, S. S. (2021). The potential diagnostic accuracy of let-7 family for cancer: A meta-analysis. *Technol. Cancer Res. Treat.* 20, 15330338211033061.

Zhang, Z. Q., Meng, H., Wang, N., Liang, L. N., Liu, L. N., Liu, S. M., et al. (2014b). Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. *Diagn. Pathol.* 9, 135. doi:10.1186/1749-8090-9-135

Zhou, Z., Lv, J., Wang, J., Yu, H., Lu, H., Yuan, B., et al. (2019). Role of MicroRNA-124 as a prognostic factor in multiple neoplasms: A meta-analysis. *Dis. Markers* 2019, 1654780.

Zhou, J. M., Wang, T., and Zhang, K. H. (2021). AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. *Medicine (Baltimore)* 100 (43), e27073. doi:10.1097/MD.00000000000027673

Zhu, W. J., Yan, Y., Zhang, J. W., Tang, Y. D., and Han, B. (2020). Effect and mechanism of miR-26a-5p on proliferation and apoptosis of hepatocarcinoma cells. *Cancer Manag. Res.* 12, 3013–3022.

Zhuang, J. P., and Meng, Z. Q. (2015). Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. *Biomed. Res. Int.* 2015, 731781.